Combined application of BNLF2b antibody with VCA-IgA, Rta-IgG, and Zta-IgA in nasopharyngeal carcinoma screening in the Guangxi region
PLOS One · 2025
DOI: 10.1371/journal.pone.0332606 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Ruilan Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Guilin Medical University, Guilin, Guangxi, China. Hauptthemen laut MEDLINE: Nasopharyngeal Neoplasms, Immunoglobulin G, Antibodies, Viral, Immunoglobulin A. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Central Government Guidance Fund for Local Science and Technology Development of Guangxi Zhuang Autonomous Region, Guangxi Science and Technology Plan Project.
Abstract (Originalsprache)
Background
This study aims to assess the diagnostic value of the Epstein-Barr virus (EBV) BNLF2b antibody(P85-Ab), alone or in combination with VCA-IgA, Rta-IgG, and Zta-IgA antibodies, in the context of nasopharyngeal carcinoma (NPC).
Methods
The study included 100 NPC patients and 100 healthy controls. Chemiluminescent microparticle immunoassay was utilized to measure P85-Ab levels in the serum samples of both NPC patients and healthy controls. Additionally, the ELISA method was employed to detect serum levels of VCA-IgA, Rta-IgG, and Zta-IgA antibodies. The study analyzed the roles of serum P85-Ab in conjunction with VCA-IgA, Rta-IgG, and Zta-IgA antibodies in the diagnosis of NPC.
Results
Serum levels of P85-Ab, VCA-IgA, Rta-IgG, and Zta-IgA antibodies in NPC patients were significantly higher than those in the normal control group (P < 0.05). The area under the receiver operating characteristic curve (AUC) for individual diagnosis of NPC using serum P85-Ab, VCA-IgA, Rta-IgG, and Zta-IgA antibodies were 0.964, 0.916, 0.838, and 0.840, respectively. The AUC for the combined detection of the four markers in diagnosing NPC was 0.996, indicating the optimal diagnostic value of the combined detection.
Conclusion
The combined detection of P85-Ab with VCA-IgA, Rta-IgG, and Zta-IgA antibodies demonstrates high diagnostic value for nasopharyngeal carcinoma. Serum P85-Ab may serve as a potential marker for the diagnosis of NPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Guilin Medical University, Guilin, Guangxi, China.
- Department of Laboratory Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region, China.
- Department of Otolaryngology & Head and Neck, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
ORCID-Profile: Yulin Yuan
Förderung
- Central Government Guidance Fund for Local Science and Technology Development of Guangxi Zhuang Autonomous Region
- Guangxi Science and Technology Plan Project
Zitieren
APA
Lin, R., Qin, R., Zhang, Y., Guan, Y., Wu, B., Li, S., Qu, S., & Yuan, Y. (2025). Combined application of BNLF2b antibody with VCA-IgA, Rta-IgG, and Zta-IgA in nasopharyngeal carcinoma screening in the Guangxi region. PLOS One. https://doi.org/10.1371/journal.pone.0332606
Vancouver
Lin R, Qin R, Zhang Y, Guan Y, Wu B, Li S, et al. Combined application of BNLF2b antibody with VCA-IgA, Rta-IgG, and Zta-IgA in nasopharyngeal carcinoma screening in the Guangxi region. PLOS One. 2025. doi:10.1371/journal.pone.0332606
BibTeX
@article{Lin2025,
author = {Lin, Ruilan and Qin, Ru and Zhang, Yunlong and Guan, Yao and Wu, Boheng and Li, Shangyang and Qu, Shenhong and Yuan, Yulin},
title = {Combined application of BNLF2b antibody with VCA-IgA, Rta-IgG, and Zta-IgA in nasopharyngeal carcinoma screening in the Guangxi region},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0332606}
}
EUVIMED